NCT01876212View on ClinicalTrials.gov

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 16, 2014

Primary Completion Date

July 11, 2018

Study Completion Date

July 31, 2019

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

DC vaccine

DRUG

Dasatinib

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Walter J. Storkus

OTHER

NCT01876212 - Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | Biotech Hunter | Biotech Hunter